Adial Pharmaceuticals (NASDAQ: ADIL)

Adial Pharmaceuticals (NASDAQ: ADIL) is advancing precision medicine for Alcohol Use Disorder with AD04, a genetically targeted therapy designed to reduce heavy drinking without requiring abstinence. In this discussion, CEO Cary Claiborne shares insights on how AD04 works, recent FDA feedback on the company’s proposed 505(b)(2) bridging strategy, and what’s next as we prepare for Phase 3 clinical trials. Learn more about how we're shaping the future of addiction treatment: https://bit.ly/4hJfmDU #AlcoholUseDisorder #PrecisionMedicine #ClinicalTrials

In this interview, Citeline's Generics Bulletin features insights from Adial Pharmaceuticals (NASDAQ: ADIL)' CEO Cary Claiborne on how the company is addressing the gap in Alcohol Use Disorder (#AUD) treatment with AD04. Unlike existing options, AD04 is a non-abstinence-based therapy targeting patients with specific genetic biomarkers, offering a personalized approach to reducing alcohol consumption. Read more: https://bit.ly/4h92CpV #PersonalizedMedicine #AddictionTreatment #Pharma

Benzinga reports that the FDA has agreed with Adial Pharmaceuticals (NASDAQ: ADIL)' proposed 505(b)(2) bridging strategy, supporting AD04’s progression to Phase 3 trials. This regulatory milestone strengthens AD04’s path forward as a potential new treatment for Alcohol Use Disorder (#AUD). With clinical supply manufacturing underway, Adial is preparing for its next phase in advancing precision medicine for addiction treatment. Read more: https://bit.ly/4imVtDe #ClinicalTrials #AddictionTreatment #PrecisionMedicine

Adial Pharmaceuticals (NASDAQ: ADIL)'s latest patent for genotype-specific addiction treatment with AD04 was featured in a recent Psychiatric Times report. The patent covers methods for identifying patients with specific genetic markers linked to substance use disorders and treating them with AD04, a selective serotonin-3 receptor antagonist. By integrating genetic diagnostics with precision medicine, this breakthrough aims to improve treatment outcomes for opioid and Alcohol Use Disorders (#AUD). Read more: https://bit.ly/41jHCa4 #PrecisionMedicine #AddictionTreatment #GeneticDiagnostics

Adial Pharmaceuticals (NASDAQ: ADIL) reports 2024 fiscal year financial results and provides business update. More here: https://bit.ly/3XQ07Cf

Adial Pharmaceuticals (NASDAQ: ADIL) is making strides in addressing Alcohol Use Disorder with its lead therapy, AD04. Cary Claiborne, CEO, discusses the promising path forward as AD04 progresses to late-stage development Phase III clinical trials. Per Pharmaceutical Executive explore the latest developments in this important area of addiction treatment: https://bit.ly/3COtcXg #AlcoholUseDisorder #Pharmacokinetics #ClinicalTrials

Adial Pharmaceuticals (NASDAQ: ADIL) has received a positive response from the FDA on its proposed in vitro bridging strategy for AD04, a key step toward advancing its Phase 3 clinical program. This confirmation aligns with Adial’s 505(b)(2) regulatory pathway strategy, ensuring compliance with FDA requirements for approval. With this regulatory milestone, Adial now moves one step closer to beginning its Phase 3 trial. Learn more: https://bit.ly/4bi7VSL #AddictionTreatment #RegulatoryPathway

Adial Pharmaceuticals (NASDAQ: ADIL) has been granted a new U.S. patent by USPTO, expanding coverage of its genetic-based approach to diagnosing and treating Alcohol Use Disorder (AUD) and other drug dependencies. This patent supports the identification of specific genetic markers to help match patients with AD04, Adial’s investigational therapy, based on their unique genetic profile. Learn more: https://bit.ly/4k7Kz64 #AddictionTreatment #Patent #PrecisionMedicine

Understanding alcohol use isn't black and white. As highlighted in CBC/Radio-Canada's article, documentary filmmaker Maureen Palmer emphasizes that harm reduction—cutting back on drinking—is often more achievable and impactful than strict abstinence. Her insights align with Adial Pharmaceuticals (NASDAQ: ADIL)'s mission to address Alcohol Use Disorder (AUD) through healthier relationships with alcohol. Read more about her thoughtful perspective: https://bit.ly/4k8egUT #HarmReduction #PublicHealth

In a recent Scrip Asks roundup, Tony Goodman, COO of Adial Pharmaceuticals (NASDAQ: ADIL), shares his insights on early-stage deals as a pathway for replenishing pipelines in biopharma. His perspective highlights the increasing focus on precision medicine in 2025. Read more in the full article from Citeline: https://bit.ly/3WElOnQ #Biopharma #PrecisionMedicine